[WEBINAR] Orphan Drug Development in Japan How can we accelerate rare disease patients' access to therapies?
March 10th: 11AM-12PM (EDT)/3PM-4PM (GMT)
Overview of current rare disease market in Japan
Highlight of recent regulatory process & requirements
Support for Orphan drugs development in Japan
Rare disease patients in Japan
Your Trusted Service Partner for Asia Clinical Trials
CMIC is the largest CRO in Japan, involved in near 80% of Japan’s new drug development and filing
Broad coverage in APAC region, supporting clinical trials in 13 countries
Unique business model (PVC) to provide end-to-end solutions
Local regulatory expertise and strong network with local opinion leaders
Connect with Us
We want to connect with you and discuss your current projects, needs and answer any questions you may have, no matter where you are in the drug development process.
Want to reach 137,000+ FierceBiotech subscribers with your own message? Contact [email protected] or call 202-824-5074.
